Cancer pain management with a controlled-release oral morphine preparation

Area of Science:

• Oncology
• Pain Management
• Pharmacology

Background:

• Advanced cancer pain management often requires continuous opioid therapy.
• Current on-demand opioid regimens can lead to suboptimal pain control and patient inconvenience.
• Controlled-release formulations offer potential for improved pain management and patient adherence.

Purpose of the Study:

• To evaluate the efficacy and acceptability of controlled-release oral morphine (MS Contin) tablets.
• To assess the switch from immediate-release oral morphine to a fixed-schedule controlled-release regimen.
• To determine if MS Contin administered every 8-12 hours is a suitable alternative for cancer pain.

Main Methods:

• An open-label pilot study involving patients with advanced cancer pain.
• Initial titration with immediate-release oral morphine sulfate every four hours.
• Subsequent switch to MS Contin tablets, initially every eight hours, then every 12 hours for some patients.
• Rescue doses of immediate-release morphine were available but infrequently used.

Main Results:

• 37 patients were maintained on an eight-hourly MS Contin schedule.
• 21 patients were successfully stabilized on MS Contin every 12 hours.
• A significant reduction (over 20%) in average daily morphine dose was observed in patients on the 12-hour schedule.
• Most patients preferred MS Contin over immediate-release morphine for convenience and pain relief adequacy.

Conclusions:

• Controlled-release oral morphine (MS Contin) administered on a fixed schedule is effective for managing advanced cancer pain.
• This regimen offers improved convenience and adequate pain relief compared to on-demand immediate-release morphine.
• MS Contin may allow for a reduction in total daily opioid dosage while maintaining pain control.